HUMAN CAPITAL INVESTMENT ON THE FINANCIAL OUTCOMES OF LISTED PHARMACEUTICAL FIRMS IN NIGERIA

Abstract

This study investigates the effect of human capital investment on the financial outcomes of listed pharmaceutical firms in Nigeria, with particular focus on how Training and Development Cost (TDC) and Employee Acquisition Cost (EAC) influence Return on Assets (ROA). An ex-post facto research design was adopted, utilizing multi-year panel data derived from audited annual reports of pharmaceutical companies listed on the Nigerian Exchange between 2015-2024. Descriptive statistics, correlation analysis, E_view version 22 was employed to determine the relationship between human capital variables and financial outcomes of listed pharmaceutical firms in Nigeria. The empirical findings show that Employee Acquisition Cost (EAC) exerts a positive and statistically significant effect on ROA across both fixed and random-effects estimations. This implies that recruitment-related spending, covering attraction, selection, and onboarding of skilled professionals, directly enhances asset utilization and financial efficiency. The result show that specialized human capital provides valuable, rare, and inimitable resources capable of improving firm performance. Conversely, Training and Development Cost (TDC) demonstrates a positive but statistically insignificant relationship with ROA, indicating that training interventions may not generate immediate financial benefits. This suggests that training outcomes in the pharmaceutical industry are often long-term, intangible, or dependent on contextual factors such as employee retention, regulatory requirements, and applicability of acquired skills. Firm size (FS) also shows no statistically significant influence on ROA, highlighting that larger asset bases do not automatically translate into superior financial outcomes. Overall, the study concludes that human capital investment—particularly employee acquisition—plays a critical role in improving the financial outcomes of Nigerian pharmaceutical firms. The study recommends strengthening recruitment processes, prioritizing the acquisition of specialized technical talent, and implementing retention strategies to ensure the long-term payoff of training investments. By disaggregating human capital investment into TDC and EAC and examining their distinct effects on ROA, the study contributes to existing literature and provides industry-specific insights into optimizing human capital strategies for improved financial performance within Nigeria’s pharmaceutical sector.